Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis

Journal of Virology

Volumn 75, Issue 1, 2001, Pages 311-322

  Zhu, Y ^a   Yamamoto, T ^a   Cullen, J ^a   Saputelli, J ^a   Aldrich, C E ^a   Miller, D S ^a   Litwin, S ^a   Furman, P A ^a   Jilbert, A R ^a   Mason, W S ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 FLUORO 5 METHYL BETA LEVO ARABINOFURANOSYL)URACIL; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; HALF LIFE TIME; HEPADNAVIRUS; HEPATITIS VIRUS; HUMAN; HUMAN CELL; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION; VIREMIA; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TITRATION; WOODCHUCK;

AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DNA, CIRCULAR; DNA, VIRAL; DRUG RESISTANCE; HEPATITIS B VIRUS, WOODCHUCK; HEPATOCYTES; KINETICS; LAMIVUDINE; MARMOTA; MOLECULAR SEQUENCE DATA;

EID: 0034749753     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.1.311-322.2001     Document Type: Article

References (46)

1. Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication
2. In vitro infection of woodchuck hepatocytes with woodchuck hepatitis virus and ground squirrel hepatitis virus
3. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group
4. Transmission of type B Viral hepatitis to chimpanzees
5. Clinical experience with famciclovir against hepatitis B virus and development of resistance
6. Hepatitis B antigens in serum and liver of chimpanzees acutely infected with hepatitis B virus
7. Role of glycan processing in hepatitis B virus envelope protein trafficking
8. Transcripts and the putative RNA pregenome of duck hepatitis B virus: Implications for reverse transcription
9. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
10. Pharmacokinetic and pharmacodynamic studies of 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl) uracil (L-FMAU) in the woodchuck model of hepatitis B virus (HBV) infection
11. Use of 2'-fluoro-5-methyl-β-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus
12. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures
13. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA
14. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks
15. Efficacy of the carbocyclic 2'-carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
16. Viral clearance without destruction of infected cells during acute HBV infection
17. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections
18. Lamivudine resistance in immunocompetent chronic hepatitis B: Incidence and patterns
19. Immunofluorescence microscopy in experimentally induced, type B hepatitis in the chimpanzee
20. Laboratory assessment of hepatic injury in the woodchuck (Marmota monax)
21. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement
22. Woodchuck hepatitis virus infections: Very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte
23. Nucleotide sequence of a cloned woodchuck hepatitis virus genome: Evolutional relationship between hepadnaviruses
24. Unique inhibitory effect of 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methyl-uracil 5'-triphosphate on Epstein-Barr virus and human DNA polymerases
25. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
26. Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: Effect on intrahepatic-viral DNA, RNA, and protein expression
27. The linking regions of EBNA1 are essential for its support of replication and transcription
28. Asymmetric replication of duck hepatitis B virus DNA in liver cells: Free minus-strand DNA
29. Lamivudine therapy of WHV-infected woodchucks
30. The role of N-linked glycosylation in the secretion of hepatitis B virus
31. Hepatitis B virus DNA forms in nuclear and cytoplasmic fractions of infected human liver
32. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus
33. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment
34. Viral dynamics in hepatitis B virus infection
35. Antiviral activity of clevudine [L-FMAU, 1-(2-fluoro-5-methyl-β-L-arabino-furanosyl) uracil] against WHV replication and gone expression in chronically infected woodchucks (M. monax)
36. Core antigen and antibody in woodchucks after infection with woodchuck hepatitis virus
37. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate
38. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification
39. Mutation in HBV DNA-dependent DNA polymerase confers resistance to lamivudine in vivo
40. Assay of transforming activity of tumor virus DNA
41. Efficient transfer of large DNA fragments from agarose gels to diazobenzyloxymethyl paper and rapid hybridization by using dextran sulfate
42. Relationship between viral DNA synthesis and virion envelopment in hepatitis B viruses
43. Covalently closed circular viral DNA formed from two types of linear DNA in woodchuck hepatitis virus-infected liver
44. Low dynamic state of viral competition in a chronic avian hepadnavirus infection
45. Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections
46. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine